Sundaram Mutual Fund Pharma Fund - Regular Plan - Growth

Sundaram Mutual Fund Pharma Fund - Regular Plan - Growth complete review for investors

Sundaram Mutual Fund Pharma Fund - Regular Plan - Growth ka primary objective hai pharmaceutical sector ke stocks mein invest karna. Ye fund pharma category mein hai aur equity mutual fund ke under aata hai. Iska investment style growth-oriented hai, jo ki long-term capital appreciation par focus karta hai. Yeh fund un investors ke liye sahi hai jo high-growth potential ki talash mein hain aur sector-specific risk ko samajhte hain. Agar aapko pharma sector ki opportunities mein vishwas hai, toh ye fund aapke liye suitable ho sakta hai. Aapne socha hoga, pharma sector ki volatility kaise kaam karti hai? Chaliye, aage badhte hain.

Sundaram Mutual Fund Pharma Fund - Regular Plan - Growth historical performance and returns

Aayiye, ab hum is fund ki historical performance par nazar dalte hain. Sundaram Mutual Fund Pharma Fund - Regular Plan - Growth ne 1 saal mein -4.48% return diya hai. Lekin agar hum 3 saal ki baat karein, toh isne 9.28% aur 5 saal mein 10.37% return generate kiya hai. Yeh returns benchmark Nifty Pharma TRI ke comparison mein hai. Yeh raha ek simple HTML table jo performance ko sahi tarike se dikhata hai:

Period	Sundaram Mutual Fund Pharma Fund Returns	Nifty Pharma TRI Returns
1 Year	-4.48%	Data not available
3 Year	9.28%	Data not available
5 Year	10.37%	Data not available

Consistency ki baat kare toh yeh fund relatively stable raha hai, lekin short-term mein volatility dikhata hai. Fund manager S. Krishnakumar ka experience bhi is fund ki performance mein important role play karta hai. Unka tenure 3.5 saal ka hai, jo ki investors ke liye ek positive sign hai. Kya aapko lagta hai yeh performance aage chal kar improve ho sakti hai?

Sundaram Mutual Fund Pharma Fund - Regular Plan - Growth top holdings and portfolio allocation

Sundaram Mutual Fund Pharma Fund - Regular Plan - Growth ke top holdings mein kuch major companies hain jaise Sun Pharmaceutical Industries Ltd. (20.5%), Dr. Reddy's Laboratories Ltd. (12.8%), Cipla Ltd. (10.4%), Divi's Laboratories Ltd. (9.8%), aur Torrent Pharmaceuticals Ltd. (7.2%). Is fund ki strategy in companies ke growth potential par based hai. Yeh fund mainly pharmaceutical sector mein invest karta hai, jo ki healthcare and wellness ko dhyaan mein rakhta hai. Sector allocation ke hisaab se, yeh fund kaafi diversified portfolio offer karta hai jis mein top players hain. Is tarike se, fund ki performance bhi in holdings par depend karti hai. Agar aap long-term investing aur portfolio diversification ki soch rahe hain, toh yeh fund kaafi interesting ho sakta hai.

Sundaram Mutual Fund Pharma Fund - Regular Plan - Growth riskometer and downside risk

Sundaram Mutual Fund Pharma Fund - Regular Plan - Growth ka riskometer "Very High" category mein aata hai. Iska matlab hai ki yeh fund market volatility ke liye kaafi sensitive hai, jo investors ke liye downside risk badha sakta hai. Agar hum Sharpe ratio ki baat karein, toh data not available hai, lekin, iska matalab hai ki aapko returns ke liye higher volatility se guzar na padega. Yeh fund un investors ke liye suitable hai jo risk ko le sakte hain aur long-term mein investment karne ki soch rahe hain. Aapne dekha hoga ki jab market girta hai, toh pharma sector bhi kabhi kabhi impact hota hai. Kya aap tayaar hain aise fluctuations ko sambhalne ke liye?

Sundaram Mutual Fund Pharma Fund - Regular Plan - Growth advantages and disadvantages

• Pros:
  • High growth potential due to strong pharmaceutical holdings.
  • Experienced fund manager with over 3 years of tenure.
  • Focused investment strategy in a high-demand sector.
  • Suitable for long-term investors looking for capital appreciation.
• Cons:
  • High volatility and risk, may not suit conservative investors.
  • 1-year performance has been negative, which is concerning.
  • Expense ratio of 1.95% could impact net returns.